Join Drs Kevin Kalinsky and Jennifer Litton as they discuss hereditary breast cancer, genetic testing, and therapeutic implications.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

PARP and PARG Inhibitors in Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/32029455/

BRCA1 and BRCA2 Mutations https://www.ncbi.nlm.nih.gov/books/NBK470239/

Iniparib Plus Chemotherapy in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/21208101/

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant https://pubmed.ncbi.nlm.nih.gov/31461380/

ER/PgR Testing in Breast Cancer Clinical Practice Guidelines (ASCO/CAP, 2020) https://reference.medscape.com/viewarticle/924542

Pathological Complete Response in Neoadjuvant Treatment of High-risk Early-stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry https://www.fda.gov/media/83507/download

Adjuvant Olaparib for Patients With BRCA1- or BRCA2-mutated Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34081848/

PALB2 Partner and Localizer of BRCA2 https://www.ncbi.nlm.nih.gov/gene/79728

Pre-specified Event Driven Analysis of Overall Survival (OS) in the OlympiA Phase III Trial of Adjuvant Olaparib (OL) in Germline BRCA1/2 Mutation (gBRCAm) Associated Breast Cancer https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/olympia-phase-iii-pre-specified-event-driven-analysis-of-overall-survival-of-olaparib-in-gbrcam-breast-cancer

Pembrolizumab for Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/

Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/28578601/

Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/30110579/

Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study https://pubmed.ncbi.nlm.nih.gov/29045554/

RAD51 Recombinase https://www.ncbi.nlm.nih.gov/gene/5888

The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/34068084/

Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq

Tissue-agnostic Drug Approvals: How Does This Apply to Patients With Breast Cancer? https://pubmed.ncbi.nlm.nih.gov/34518552/